Treatment AI Passes Medical School Clinical Exam with 92% Success Rate
VANCOUVER, British Columbia, March 20, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce that it’s AI medical information support platform was used in the “Objective Structured Clinical Examination” (“OSCE”), a standard clinical exam of diagnostic aptitude at medical and nursing schools, passing the exam with a 92% success rate. Treatment gave a third-year non-medical college student the Treatment mobile app and had them join a class of third-year medical school students taking their annual clinical exam. The OSCE exam is a standard exam given at medical, nursing and other professional healthcare schools. They are integral in medical education, as they allow a student to practice and demonstrate clinical diagnostic skills in an artificial medical scenario. During the exam, students enter an exam room to assess an actor who has been instructed on imitating a patient with a specific disease. Passing the OSCE is a national requirement for graduation in 57 countries worldwide (including US, Canada and United Kingdom) for medical and nursing students. In this case, Treatment gave the student its Treatment AI mobile app and sent them in to examine 12 ‘simulated’ patients. The student used the app to ask the patient questions, then left the room and wrote a clinical note summarizing the findings and suggesting the most likely possible diagnoses. The college student, with no previous medical training, entered the simulated patient’s age, sex, and initial symptom, and followed the prompts to complete an individualized assessment.The student then used the information summarized by the application to write a medical note describing the history, exam, recommended labs, and diagnoses. The student passed the exam, getting 11 of 12 “1st most likely” diagnoses correct. This included the student successfully making a variety of complex diagnoses including colon cancer, appendicitis, acute myocardial infarction, diabetes, and patellar tendonitis. Dr. Kevin Peterson, MD, MPH, Chief Medical Officer stated “The ability of the AI software to identify the pertinent positives and negatives, together with physical exam findings, and turn them into a precise description and reasoned differential diagnoses was remarkable. This is an AI tool that any medical professional can use in their pocket.” Dr. Essam Hamza, MD, CEO of Treatment.com AI added “We are extremely excited with the power and accuracy of our AI Medical diagnostic engine and the faith medical schools have in utilizing it, for testing and training the medical professionals of tomorrow. This underlying software is also the foundation of new products we are planning to launch in the healthcare marketplace later this year, in our mission to dramatically disrupt how healthcare is delivered worldwide” Treatment.com AI provides solutions for medical education and clinical information support. The Medical Education Suite (MES) provides case-based clinical decision making testing, grading and remedial action support for the next generation of healthcare professionals. The goals for MES are to enable better performance for Medical School students in their national exams (including OSCE) and for Schools, to reduce administration and exam creation costs, as well as minimizing valuable time for faculty in administering and grading exams. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com If you would like to find out more about our products and services including our OSCE support, please email: info@treatment.com For media enquiries contact: media@treatment.com Call: +1 (612) 788-8900 / Toll Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Treatment.com AI Inc. Closes over-subscribed non-brokered private placement of $2,908,200
Vancouver, British Columbia, March 14, 2024 – Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that, further to its news release dated February 16, 2024, it has closed a non-brokered private placement of 6,295,500 special warrants of the Company (each, a “Special Warrant”) at a price of $0.40 per Special Warrant, for aggregate gross proceeds of $2,518,200 and 975,000 units of the Company (each, a “Unit”) at a price of $0.40 per Unit, for aggregate gross proceeds of $390,000 (the “Offering”). Each Special Warrant will automatically convert without payment of any additional consideration into one Unit on the date that is the earlier of (i) the third business day after a) a receipt from the applicable securities regulatory authorities for a (final) short form prospectus (a “Qualifying Prospectus”) or b) the date of filing a prospectus supplement (the “Prospectus Supplement”) to a short form base shelf prospectus qualifying the distribution of the Units issuable upon the conversion of the Special Warrants, and (ii) 4 months and one day after the issue date of the Special Warrants. Each Unit is comprised of one common share of the Company (each, a “Share”) and one-half of one share purchase warrant (each whole, a “Warrant“) of the Company, with each Warrant exercisable into one additional Share at an exercise price of $0.60 for two (2) years from the date of closing. Dr. Essam Hamza, CEO of the Company, stated: “We are very encouraged with the overwhelming response to the financing and the subsequent over-subscription. This money will help our aggressive growth plans over the next year.” In connection with the Offering, the Company has paid finder’s fees totalling $220,816 and issued an aggregate 552,040 non-transferable broker warrants (the “Broker Warrants”) to arm’s-length parties. Each Broker Warrant entitles the holder to purchase one Common Share (a “Broker Share”) at an exercise price of $0.60 per Broker Share for a period of two (2) years from the date of closing. The Company intends to use the proceeds raised from the Offering for working capital purposes. Prior to the filing of a Qualifying Prospectus or a Prospectus Supplement, the Special Warrants and the securities issuable upon conversion of the Special Warrants are subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The Units and Broker Warrants are subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The Special Warrants and Warrants will not be listed on any stock exchange or over-the-counter market. The securities issued pursuant to the Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com 1 (612) 788-8900 Toll Free: 1 (888) 788-8955 Cautionary Statement This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Offering, the use of proceeds of the Offering, the filing of a final prospectus or a prospectus supplement and future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
Treatment.com AI Provides Corporate Update
Bolstering the Leadership Team The Global Library of Medicine Passes Milestone of 1000+ Diseases Treatment Provides Platform to Support Healthcare in Nairobi, Kenya VANCOUVER, British Columbia, February 29, 2024 – Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to provide a general corporate update. Treatment has been working diligently to continue its acceleration into the US market. A few key milestones the Company has accomplished are as follows: Bolstering the Leadership Team Dr. Essam Hamza, MD – Appointed Chief Executive Officer & Director The appointment of Dr. Hamza follows a mandate to appoint a leader with a rare combination of extensive healthcare, technology and capital markets experience capable of leading the Company through the next phase of its growth. Dr. Hamza is a proven executer with a track record of successfully founding, leading and growing transformational healthcare companies. Most recently, he was the Founder, a Director and CEO of CloudMD, a Vancouver based healthcare technology company. Dr. Hamza is a seasoned and highly successful business visionary, steeped in medical and healthcare experience via his over 20 years as a medical doctor and a business builder as the founder of several healthcare companies including CloudMD Inc. From 2019 to 2022 at CloudMD, Dr. Hamza lead the company through tremendous growth, from a handful of employees and approximately $4M in annual sales in Canada, to hundreds of employees and customers across North American and over $100M in annual sales. Mr. David Worner – Appointed Chief Financial Officer Mr. Worner is currently the Chief Executive Officer & Founder of GrowthPath Partners, a transactional accounting & advisory firm that services companies going through mergers and acquisitions and public offering events. Prior to founding GrowthPath, Mr. Worner was a Partner at NOW CFO, an outsourced chief financial officer and financial consulting firm. Prior to NOWCFO, Mr. Worner has worked at private-equity backed and public companies. Mr. Worner started his career in public accounting. Mr. Worner earned an undergraduate degree in Accounting from the University New Orleans. Dr. Kevin Peterson – Appointed Chairman & Chief Medical Officer Dr. Kevin Peterson is the Founder and Chief Medical Officer of Treatment.com AI Inc. He is a Professor Emeritus of Family Medicine at the University of Minnesota (UMN) Medical School and Vice President of Primary Care at the American Diabetes Association. Prior to coming to Treatment, Dr. Peterson directed the UMN Center of Excellence in Primary Care and the UMN Research Evaluation and Commercialization Hub, with additional academic appointments in the Institute for Engineering in Medicine and the Institute for Health Informatics. A fellow of the Royal College of Surgeons of Edinburgh and the American Academy of Family Physicians, Dr. Peterson has worked extensively with the National Institutes of Health and published hundreds of scientific articles and publications on diabetes, medical engineering, clinical trials, and practice-based research. His work continues to focus on the dissemination and implementation of evidence-based methods to improve health care delivery in community settings. Dr. Peterson serves as Chairman of the Board of Directors and leads the medical providers who have built the Global Library of Medicine. Platform Enhancements – The Global Library of Medicine Passes Milestone of 1000+ Diseases The Global Library of Medicine (the “GLM”) has been further expanded to include over 1,000 diseases & >10,000 symptoms and risk factors. This includes coverage of most common diseases. It is important to note that the GLM recognizes the “most likely diagnosis can vary” depending on the geography of the patient even if the patient presenting symptoms are similar. Whilst utilizing AI, the GLM has been curated & evaluated by 150+ physicians globally to be correct, reliable and accurate. Perpetual evolution of the platform is both through machine learning & peer review. Impact – Treatment Provides Software to Support Healthcare in Nairobi, Kenya Treatment has made its platform available to healthcare workers providing valuable support to patients in the underserved communities of Nairobi. These healthcare workers have access to about 50 medicines but are often poorly trained in diagnostic approaches. Treatment’s platform provides clinical decision support to assist the healthcare workers in making an accurate diagnosis. All interactions and symptoms can then be sent and reviewed by a doctor at a local hospital. Marketing Agreement Further, the Company has engaged Sunburst Data Corp. of Vancouver, BC (“Sunburst”) to provide digital marketing and advertising of the Company’s business and products for a period of six months commencing February 26, 2024, in consideration of an aggregate of CAD $400,000, pursuant to an agreement dated February 26, 2024. Sunburst does not currently own any interest, directly or indirectly, in the Company or its securities. FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@treatment.com Cautionary Statements This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Treatment.Com International Inc. Announces Closing Of Non-Brokered Private Placement
Vancouver, British Columbia, October 5, 2023 – Treatment.com International Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce, further to its news release on September 28, 2023, the Company has completed its previously announced non-brokered private placement of common shares in the capital of the Company (each, a “Common Share”) at a price of $0.15 per Common Share (the “Offering”), for aggregate gross proceeds of $371,250. The Company intends to use the proceeds raised from the Offering for working capital purposes. All securities issued in connection with the Offering are subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The securities issued pursuant to the Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. Release issued by: Kevin Peterson, Interim CEO Main Line: +1 (612) 788-8900 Toll Free USA/Canada: +1 (888) 788-8955 Cautionary Statement This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Offering and the use of proceeds of the Offering are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
Treatment.Com International Inc. Closes Non-Brokered Private Placement and Debt Settlement
Vancouver, British Columbia, September 29, 2023 – Treatment.com International Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that further to its news release dated August 18, 2023, the Company has completed the previously announced non-brokered private placement of common shares in the capital of the Company (the “Common Shares”) at a price of $0.10 per Common Share for aggregate gross proceeds of $1,000,000 (the “Offering”) and the previously announced debt settlement of $1,800,000 (the “Debt Settlement”). The Company issued 18,000,000 Common Shares at $0.10 per Common Share to settle $1,800,000 liabilities of the Company. The Company obtained shareholders’ approval with respect to the Offering and the Debt Settlement. The Offering was completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions. Accordingly, the Common Shares issued in the Offering are not subject to a statutory hold period in accordance with applicable Canadian securities laws. There is an offering document related to the Offering, which can be accessed under the Company’s profile at www.sedarplus.ca and at https://treatment.com/. Prospective investors should read this offering document prior to making any investment decisions. In connection with the Offering, the Company paid a finder’s fee to an eligible finder (the “Finder”) equal to: (i) a cash commission in the amount of $17,500, being 7.0% of the aggregate gross proceeds raised from investors introduced by the Finder; and (ii) 175,000 non-transferable share purchase warrants (each, a “Finder’s Warrant”), being 7.0% of the aggregate Common Shares purchased by investors introduced by the Finder, in consideration for the Common Shares purchased by investors introduced by the Finder. Each Finder’s Warrant entitles the holder thereof to acquire one (1) Common Share at a price of $0.255 per Common Share until September 29, 2025. The Company intends on using the net proceeds of the Offering for general working capital purposes. The securities issued pursuant to the Offering have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws. Accordingly, the securities issued pursuant to the Offering may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful. Release issued by: Kevin Peterson, Interim CEO Main Line: +1 (612) 788-8900 Toll Free USA/Canada: +1 (888) 788-8955 Cautionary Statement This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, the use of proceeds of the Offering, and future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law. Neither the Canadian Securities Exchange nor its regulation services provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Treatment.Com International Inc. Announces Non-Brokered Private Placement of Up To $500,000
Vancouver, British Columbia, September 28, 2023 – Treatment.com International Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce a non-brokered private placement of up to 3,333,333 common shares in the capital of the Company (each, a “Common Share”) at a price of $0.15 per Common Share (the “Offering”), for aggregate gross proceeds of up to $500,000. The Company intends to use the proceeds raised from the Offering for working capital purposes. The Offering is expected to close on or before October 10, 2023. The Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange. All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions. The securities issued pursuant to the Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. Release issued by: Kevin Peterson, Interim CEO Main Line: +1 (612) 788-8900 Toll Free USA/Canada: +1 (888) 788-8955 Cautionary Statement This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Offering, the use of proceeds of the Offering, and future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
Treatment.com International Inc. Announces Private Placement And Debt Settlement
Vancouver, British Columbia, August 18, 2023 – Treatment.com International Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce it has arranged a private placement of $1,000,000 issuable for 10,000,000 shares (the “Private Placement”). Additionally, the Company will settle up to $1,800,000 of Company liabilities at a price of $0.10 per share for up to 18,000,000 shares (the “Debt Settlement”). The Private Placement and Debt Settlement are being completed pursuant to a price reservation filed July 25, 2023. Closing of the financing is subject to the Canadian Securities Exchange approval and shareholder approval pursuant to the policies of the Canadian Securities Exchange. The Private Placement is being conducted pursuant to National Instrument 45-106, Part 5A, Listed Issuer Finance Exemption. There is an offering document related to the Private Placement that can be accessed under the Company’s profile at www.sedarplus.ca and at and at https://treatment.com/. Prospective investors should read this offering document before making an investment decision. The net proceeds of the Private Placement are expected to be used for general working capital purposes. No Finder’s fees are payable in connection with the Private Placement. The securities issued pursuant to the Private Placement have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. About Treatment.com Treatment.com is a disruptive artificial intelligence platform providing healthcare organizations and medical professionals with access to intelligent, personalized, diagnostic and treatment resources. Based on a neural network of high quality validated medical knowledge covering over 1,000 diagnoses and tens of thousands of symptoms, findings, laboratory tests, and risk factors, the company provides access to the Global Library of Medicine using sophisticated interfaces that speed the integration of diagnostic and treatment capabilities into new or existing software. For more investor information on Treatment.com please visit https://treatment.comors/. Release issued by: Kevin Peterson, Interim CEO Main Line: +1 (612) 788-8900 Toll Free USA/Canada: +1 (888) 788-8955 Cautionary Statement This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Private Placement, the use of proceeds of the Private Placement, and future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law. The Canadian Stock Exchange, nor its regulation service provider, accept responsibility for the adequacy or accuracy of this news release.
Treatment Announces Convertible Debenture Private Placement
VANCOUVER, British Columbia, March 28, 2022 (GLOBE NEWSWIRE) — Treatment.com International Inc. (“Treatment or the “Company”) (CSE: TRUE; OTC: TREIF; FFA: 939), a global healthcare company that has developed a next-generation AI platform to help patients and caregivers around the world make better health decisions, announces the proceeding of a non-brokered private placement, raising aggregate gross proceeds of up to $1,250,000 in unsecured convertible debentures (the “Private Placement”). Each debenture will consist of a $1 principal amount of unsecured, non-redeemable 8% convertible debentures, maturing 36 months from issuance, and convertible at the option of the debenture holder into units at the Company at a conversion price of $0.41 per unit. Upon conversion, each unit will be comprised of one common share and one common share purchase warrant, each warrant exercisable at a price of $0.50 for a period of two years from issuance. Interest at a rate of 8% per annum will be paid to debenture holders monthly in arrears. At the election of the Company, interest may be paid in units of the Company issued at the prevailing market price of the Company’s common shares at the time of election by the Company. The Company may pay finders’ fees in connection with the private placement. In addition to the statutory hold period as required under securities laws, the units issuable upon conversion of the debentures will be subject to a contractual hold period of twelve months from closing. The net proceeds of the private placement will be used for general working capital purposes.
Treatment Appoints Drew Zimmerman to its Board of Directors
Vancouver, B.C. March 7, 2022 – Treatment.com International Inc. (“Treatment” or the “Company”) (CSE: TRUE; OTC: TREIF; FFA 939), a global healthcare technology company that has developed a next generation AI platform to help patients and caregivers around the world make better health decisions, is pleased to announce the appointment of Mr. Drew Zimmerman to the Board of Directors of the Company. Mr. Zimmerman has been involved in public markets for ten years, eight of which were at a National brokerage firm as an Investment and Commodity Advisor before becoming a Derivatives Portfolio Manager. In that role Mr. Zimmerman has provided commodity and financial market analysis on BNN, Moneytalks Radio, HoweStreet Radio and at Investment Conferences. Mr. Zimmerman is a CFA® charter holder and holds a Bachelor of Commerce in International Business from the University of Victoria.
Treatment’s Doctor-Built Digital Health App now on Google Play Store
VANCOUVER, British Columbia, Feb. 17, 2022 (GLOBE NEWSWIRE) — Treatment.com International Inc. (“Treatment” or the “Company”) (CSE: TRUE; OTC: TREIF; FFA 939) is a global healthcare technology company that has developed a next-generation AI platform to help patients and caregivers around the world make better health decisions. After a successful launch on the Apple App Store, Treatment’s revolutionary symptom assessment tool, Treatment Digital Health App, is now available to millions more smartphone users through the Google Play Store. Powered by Treatment’s proprietary medical AI engine and their groundbreaking Global Library of Medicine (GLM), the Treatment Digital Health App provides the most advanced access to medical knowledge ever available for widespread use. “We’ve been pleased to receive overwhelmingly positive reviews on the Apple App Store for our first-even product launch, including from qualified sources like medical doctors. With so many global users accessing information via Samsung Galaxy smartphones and other digital products, we are confident that this launch on the Google Play Store will go a huge step further towards fulfilling the growing, global need for up-to-date, credible health information,” says John Fraser, CEO of Treatment. The Treatment Digital Health App’s health assessments go beyond what users might find through a typical online search, as the results are generated using up-to-date estimates of disease rates, current estimates of geographic variation, and the latest medical research. Doctors around the world currently trust Treatment’s AI software to provide information for their clinical assessments, and the same technology is used by leading medical schools to test students’ clinical skills. Now, even more users will have access to the same groundbreaking technology through the Treatment Digital Health App. At the heart of the Treatment Digital Health App sits Treatment’s innovative Global Library of Medicine (GLM) and their powerful AI engine — together, these form an advanced, scalable medical intelligence platform providing global diagnoses and treatment protocols that can be tailored to accommodate local needs. “Our Comprehensive Symptom Assessment process is like nothing else on the marketplace and is a sign of the innovative products on Treatment’s product release plan for 2022,” says Dr. Paul A. Markham, Treatment’s Chief Strategy Officer. “With this launch on the Google Play Store, the Treatment Digital Health App will be available to millions more potential users looking for a way to manage their health in what has become the COVID era of healthcare,” stated Dr. Markham. The Treatment Digital Health App is available worldwide on the Apple App Store and the Google Play Store.